-The Hindu Amid protests and a walkout by Opposition MLAs in the Assembly, the ruling Bharatiya Janata Party on Tuesday pushed through a new Gujarat Lokayukta Aayog Bill, 2013 that ostensibly seeks to end the role of the Governor and the Chief Justice of the High Court in appointing the ombudsman. The Bill proposes a seven-member selection panel headed by the Chief Minister, which will recommend a candidate for the Lokayukta's post...
More »SEARCH RESULT
Total Matching Records found : 2490
SC’s Glivec ruling setback to foreign pharma firms -Vidya Krishnan and CH Unnikrishnan
-Live Mint SC rejects Novartis's patent plea for Glivec, says it does not meet any standard of novelty or inventiveness In a landmark judgement, India's apex court rejected Swiss drug maker Novartis AG's legal challenge aimed at securing a patent for blockbuster anti-cancer drug imatinib mesylate, branded Glivec in the country. The verdict, which is seen as a setback to multinational pharmaceutical companies operating in India, may influence a rash of pending disputes...
More »Towards a gender-just society-Zoya Hasan
-The Hindu The Justice Verma Committee report acts as a blueprint for the radical transformation of gender relations within the framework of constitutional guarantees and gender equality. However, the adoption of the Criminal Law Amendment Act 2013 by Parliament on March 19, 2013, does not go beyond legal change. Prof. Hasan argues that if political parties are serious about the rights of women, the Women's Representation Bill must be passed...
More »Artful claims can’t decide patent law: court-J Venkatesan
-The Hindu The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis' claim for patent for its cancer drug. A Bench of Justices Aftab Alam and Ranjana Desai said, "We certainly do not wish the law of patent... to develop on the lines where there may be a vast...
More »Novartis order may force pharma MNCs to change
-The Economic Times Foreign pharma companies could be forced to overhaul their strategy for the Indian market by striking more local deals and cutting sky-high drug prices after the Supreme Court slammed the door on Swiss giant Novartis' attempts to gain a patent for its blood cancer-busting drug Glivec. But the ruling, welcomed by activists campaigning for affordable drugs and local generic companies, threatened to reinforce a narrative that India...
More »
